MaxCyte and Imugene, page-21

Thanks so much for the link.


“By leveraging our scalable cell-engineering process and optimized clinical manufacturing workflow, Imugene is rapidly moving towards a potential Phase 2 registrational trial for azer-cel in cancer,” said Maher Masoud, President and CEO of MaxCyte. “Our technology has been integral to the manufacturing of the allogeneic T-cell immunotherapies and was efficiently transferred from Precision Biosciences when Imugene obtained global rights for azer-cel from Precision in August 2023. With our new partnership, we will continue to support the development of azer-cel along with additional novel cell therapy programs.”
“Imugene is passionate about bringing effective new treatments and options to cancer patients,” said Leslie Chong, CEO and Managing Director at Imugene. “We were able to make a seamless transition from Precision and finalized optimization of our processes for GMP manufacturing of azer-cel in our state-of-the-art facility in North Carolina using MaxCyte’s technology, giving us the ability to scale and move forward quickly with this drug product in the future.”
MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically validated electroporation technology for complex and scalable cell engineering. The ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics by providing high transfection efficiency, seamless scalability and enhanced functionality. Imugene is MaxCyte’s 25^th SPL overall, which generates pre-commercial milestone revenue, the vast majority of which includes post-commercial revenue.



At first sight just a formal act, part of the transition.

But MaxCyte wouldn't waste their capabilities if Azer-Cel wouldn't be a potential income earner for IMU and therefore for them too. There is a huge demand for cells due to many comps jumping on the cell therapy train and long waiting times up to 2 years apply ( quote CHM CEO ) for new players if they have to source their cells from contractors. IMO this is an indirect endorsement by a NASDAQ listed company and accredited cell manufacturer that Azer-Cel is the real deal. The first US Bio cell heavyweight to show the ASX what's to come. How long will it take for the ASX to wake up? Until a virus manufacturer comes along and secures the mass CF33 production?

GLTA